Regulatory31 October 2026
Weltruza Olanzapine Injection Gets FDA Approval in Schizophrenia
In the SOLARIS trial, Weltruza lowered schizophrenia symptom scores by 9.75 to 11.27 points more than placebo at 8 weeks, with more weight gain and no peer-reviewed report yet. It is not approved in the UK or EU.